Erowid References Database
|
Waehtel H, Dorow R.
“Dual Action On Central Dopamine Function Of Transdihydrolisuride, A 9, 10-dihydrogenated Analogue Of The Ergot Dopamine Agonist Lisuride”.
Life Sciences. 1983;32:421-432.
|
|
Abstract
Transdihydrolisuride (TDHL), a 9,10-dihydrogenated analogue of the ergot dopamine (DA) agonist lisuride (LIS), was investigated for its influence on central dopaminergic functions in rats and mice after single i.p. administration. TDHL (0.39-25 mg/kg) unexpectedly induced catalepsy and antagonized apomorphine-induced stereotypies in rats; it was approx. 3-5 times less potent than the DA antagonist haloperidol. TDHL (0.025-6.25 mg/kg) caused hypokinesia and antagonized the apomorphine-induced hyperactivity in rats. Pretreatment with TDHL (0.78-12.5 mg/kg) which per se did not alter thermoregulation at room temperature, antagonized the hypothermia induced by the DA agonist apomorphine (5 mg/kg i.p.) in mice. These DA antagonistic properties contrasted with the prolactin (PRL) lowering effect of TDHL (0.01-10 mg/kg p.o.) in reserpinized female rats thus indicating DA agonist function. PRL inhibition tended to be longer lasting (8h) than after LIS (0.01-1 mg/kg p.o.) with comparable potency. In healthy volunteers TDHL (0.2-1 mg p.o.) effectively lowered PRL levels with similar potency but,with a markedly longer duration of action than LIS (724h after 0.5 mg TDIIL). In contrast to the side effects after acute LIS treatment, no comparable adverse reactions such as nausea, emesis or postural hypotension typical for DA agonists could be observed with effective PRL lowering doses of TDHL. The unique profile-of TDHL on DA functions suggests its usefulness as a potent, long lasting PRL inhibitor with less unwanted effects. The behavioural findings indicate the potential usefulness of TDHL as a neuroleptic, which due to its partial DA agonistie action, should lack typical extrapyramidal or neuroendocrine side effects of classic DA receptor blocking agents. Possible implications of the dual function of TDHL upon central DA receptors are discussed with regard to the incidence of side effects or selectivity of action for other conceivable therapeutic indications.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
